Ashok Nair, Managing Director, RPG Life Sciences Ltd
RPG Life Sciences Limited has made its second acquisition in two months in the active pharmaceutical ingredients (API) segment, and the company has an appetite for more, says a top executive with the company.The company’s wholly-owned subsidiary, RPG Active Pharma Limited (RPGAP) had on Thursday, entered into a Business Transfer Agreement to acquire the API and intermediates business of Raghava Life Sciences Private Limited on a going-concern basis through a slump sale, for a consideration of upto ₹135 crore, it said. Just last month, RPGLS had agreed to transfer its API business to RPG Active Pharma Ltd, even as it has announced plans to acquire Actis Generics Private Ltd – a Visakhapatnam-based API manufacturing company.“We are actively evaluating opportunities that can strengthen our manufacturing footprint,” Ashok Nair, RPGLS Managing Director told businessline, adding that they were mindful of cost benefits and were looking for a domestic facility that had regulatory approvals from the United States Food and Drug Administration (USFDA).More to ComeThe committed amount is about ₹700 crore for acquisitions, of which about ₹215 crore has been used. he said, referring to its investment agreement with InvAscent, a healthcare-focused private equity investor, that has invested in RPGAP. InvAscent was to initially invest up to ₹243 crore in RPGAP, with a combined PE-backed committment of upto ₹700 crore in RPGAP in tranches. “There are more (acquisitions) on cards and we would like to infuse the balance for what we have kept ..in the next 12 months,” Nair said.The latest acquisition consolidates the company’s buy-and-build strategy to bolster growth and create an integrated, scaled API focused organization, the company said. Following the recent acquisition of Actis Generics, the latest transaction broadens RPGAP’s manufacturing base, product portfolio, regulatory capabilities and customer access across geographies, it added.Bigger PortfolioThe consolidated company increases RPGAP’s manufacturing capacity from 110 KL to 505 KL, employee strength from 217 to 500 plus, with a portfolio of 22 high-value commercialised products, Nair said, adding that all employees will be retained. While the product pipeline increases from from 14 to 45, the research basket increased from 12 to 28, he said.The latest transaction includes a business with revenues of about ₹19 Crores in FY26 (unaudited) along with manufacturing facilities, R&D facility and portfolio of 29 API molecules of which 22 are commercialized and 7 are under development. “No shares are being purchased in any entity and no entity is being acquired,” the company told the stock exchange.New strengthsRaghava Life Sciences operates a modern API manufacturing facility near Hyderabad, spread across approximately 9 acres, with around 300 KL of installed capacity and a dedicated research set-up, RPG said. “The facility is WHO-GMP and EU-GMP approved with significant investment towards capacity expansion in recent years. Its established regulatory approvals, meaningful installed capacity and chemistry capabilities provide RPGAP with a high-quality manufacturing presence,” it added.The business has developed a portfolio of high-growth APIs, comprising 22 commercialized products and seven development-stage assets across diabetes, cardiovascular, CNS and other therapeutic segments. The portfolio includes commercially attractive molecules and has multiple international regulatory credentials, besides a broad basket of commercialized and pipeline APIs, it added.Lohith Ponguleti, Managing Director, Raghava Life Sciences Private Limited, said in the statement, “Over the years, we have built a differentiated business anchored by an EU-GMP (good manufacturing practices) approved manufacturing facility, strong technical capabilities and a portfolio with significant growth potential.”Published on September 3, 2026
